FDA Approves Inclisiran
Today the FDA announced the approval of inclisiran (Leqvio) as a treatment for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional low-density lipoprotein cholesterol (LDL-C) lowering. Inclisiran is an injection administered in the doctor’s office twice a year to be used along with diet and maximally tolerated statin therapy and may reduce circulating levels of LDL-C up to 51%.
Related Posts
Categories
Tags
#RaceToSaveMoreHearts advocacy cholesterol Cholesterol Management community COVID-19 COVID-19 and FH diagnosis diet Elevated Lipoprotein(a) Elevated Lp(a) Elevated Lp(a) Story familial hypercholesterolemia Family Heart Ambassador family heart disease family screening FH FH Advocate for Awareness FH Awareness Day FH Diagnosis FH Story Global Call to Action on FH Heart attack Heart Disease heart healthy high cholesterol High Lipoprotein(a) High Lp(a) HoFH Homozygous familial hypercholesterolemia LDL cholesterol Lipoprotein(a) Living Well with FH Living with familial hypercholesterolemia living with FH Living with HoFH low fat Lp(a) Patient Story PCSK9 Inhibitor PCSK9i Personal Story Policy research Treatment
Share This:
About the Author: Cat Davis Ahmed
